Is there room for non-dopaminergic treatment in Parkinson disease?
- Abraham LiebermanAffiliated withMuhammad Ali Parkinson Center, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center Email author
- , Narayanan KrishnamurthiAffiliated withMuhammad Ali Parkinson Center, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.
KeywordsParkinson disease Levodopa Non-dopaminergic drugs Non-motor symptoms
- Is there room for non-dopaminergic treatment in Parkinson disease?
Journal of Neural Transmission
Volume 120, Issue 2 , pp 347-348
- Cover Date
- Print ISSN
- Online ISSN
- Springer Vienna
- Additional Links
- Parkinson disease
- Non-dopaminergic drugs
- Non-motor symptoms
- Industry Sectors